3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
2
Tumor-Agnostic
1
Thoracic
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
109
pembrolizumab
93
Pemetrexed
83
Cisplatin
67
Specimen Handling
41
durvalumab
36
Paclitaxel
36
Nivolumab
33
Docetaxel
33
atezolizumab
30
Magnetic Resonance Spectroscopy
30
osimertinib
29
Radiotherapy
21
Gemcitabine
21
Etoposide
21
130-nm albumin-bound paclitaxel
19
Cetuximab
17
amivantamab
14
Radiosurgery
13
Radiation
12
Platinum
12
Bevacizumab
12
lazertinib
11
cemiplimab
11
Taxes
11
Immunoglobulin G
11
Topotecan
10
Ipilimumab
10
Drug Therapy
10
Disulfides
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Diphenhydramine
×
Thoracic
×
30 days
×
Clear all
NCT04165096
2026-05-13
MK-3475-01C
Merck Sharp & Dohme LLC
Phase 2
Completed
128 enrolled
14 charts